


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

Cancel claims 1, 3-9 and 12-15 and replace them with new claims 16-24 as follows:

16(Currently amended).


A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
wherein,

M, M1, and M2, independently are CH;



R represents hydrogen, or C₁₋₆ alkyl;

X represents -(CHR₇)_p-,

Y represents -(CH₂)_r-, -CO(CH₂)_n-, -SO₂-, -O-, -S-, -CH(OR')-, or CONR';

R' represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, said alkyl, and heterocyclyl, ~~aryl or heteroaryl~~ optionally substituted with 1-3 groups selected from R^a;

or, R' and R₆ taken together with the intervening N atom of CONR' of Y to form a 4-10 membered carbocyclic or heterocyclic ring optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

Q represents N, CR_Y, or O, wherein R₂ is absent when Q is O;

R_Y represents H, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-5 groups selected from R^a;

or, R₂-Q-R₃ form a 3-15 membered carbocyclic or heterocyclic ring or fused ring, optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-5 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R_w represents H, C₁₋₆ alkyl, -C(O)C₁₋₆ alkyl, -C(O)OC₁₋₆ alkyl, -SO₂N(R)₂, -SO₂C₁₋₆ alkyl, -SO₂C₆₋₁₀ aryl, NO₂, CN or -C(O)N(R)₂;

R₂ represents hydrogen, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -(CH₂)_nCOOR, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nNHR₈, -(CH₂)_nN(R)₂, -(CH₂)_nNHCOOR, -(CH₂)_nN(R₈)CO₂R, -(CH₂)_nN(R₈)COR, -(CH₂)_nNHCOR, -(CH₂)_nCONH(R₈), aryl, -(CH₂)_nC₁₋₆ alkoxy, CF₃, -(CH₂)_nSO₂R, -(CH₂)_nSO₂N(R)₂, -(CH₂)_nCON(R)₂, -(CH₂)_nCONHC(R)₃, -(CH₂)_nCOR₈, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of R^a;

R₄ and R₅ independently represent hydrogen, C₁₋₆ alkoxy, OH, C₁₋₆ alkyl, SO₃H, (CH₂)_nOPO(OH)₂, O(CH₂)_nOPO(OH)₂, CF₃, nitro, or halogen where said alkyl, and alkoxy, are optionally substituted with 1-7 groups of R^a;

R₆ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nC₅₋₁₀ heteroaryl, (C₆₋₁₀ aryl)O-, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₃₋₈ cycloalkyl, -COOR, -C(O)CO₂R, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a;

R₇ represents hydrogen, C₁₋₆ alkyl, -(CH₂)_nCOOR or -(CH₂)_nN(R)₂,

R₈ represents -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_n 3-10 heterocyclyl, C₁₋₆ alkoxy or -
(CH₂)_nC₅₋₁₀ heteroaryl, said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3
groups selected from R^a;

R₉ represents C₁₋₁₀ alkyl, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀
heterocyclyl, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nC₅₋₁₀ heteroaryl, or -N(R)₂ wherein said alkyl,
alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with 1-3
groups selected from R^a;

R^a represents F, I, CF₃, N(R)₂, NO₂, -COR₈, -CONHR₈, -CON(R₈)₂, -O(CH₂)_nCOOR, -
NH(CH₂)_nOR, -OCF₃, -NHCOR, -SO₂R, -SO₂NR₂, -SR, (C₁-C₆ alkyl)O-, -
(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, (aryl)O-, (C₁-C₆ alkyl)S(O)_m-, H₂N-C(=NH)-,
(C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)NH-, -(C₁-C₆ alkyl)NR_w(CH₂)_nC₃₋₁₀
heterocyclyl-R_w, -(C₁-C₆ alkyl)O(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)S(CH₂)_nC₃₋₁₀
heterocyclyl-R_w, -(C₁-C₆ alkyl)-C₃₋₁₀ heterocyclyl-R_w, -(CH₂)_n-Z¹-C(=Z²)N(R)₂, -
(C₂₋₆ alkenyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)O(CH₂)_nC₃₋₁₀
heterocyclyl-R_w, -(C₂₋₆ alkenyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)-C₃₋₁₀
heterocyclyl-R_w, -(C₂₋₆ alkenyl)-Z¹-C(=Z²)N(R)₂, -(CH₂)_nSO₂R, -(CH₂)_nSO₃H, -
(CH₂)_nPO(OR)₂, -(CH₂)_nOPO(OR)₂, -O(CH₂)_nSO₂R, -O(CH₂)_nPO(OR)₂, -O
(CH₂)_nOPO(OR)₂, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl,
pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C₂₋₆ alkenyl,
and C₁-C₁₀ alkyl, said alkyl, alkenyl, alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl,
isoxazolyl, thiazolyl, thienyl, furyl, and isothiazolyl optionally substituted with 1-3 groups
selected from C₁-C₆ alkyl, COOR, SO₃H, OH, F, Cl, Br, I, and -
O(CH₂)_nCH(OH)CH₂SO₃H;

Z¹ and Z² independently represents NR_w, O, CH₂, or S;

m is 0-3;

n is 0-3;

q is 0-2;

r is 1-6 and

p is 0-2.

17(Original). A compound according to claim 16 wherein Y is $-\text{CO}(\text{CH}_2)_n$, $-(\text{CH}_2)_r$ or $\text{CH}(\text{OR})$ and Q is N or CR_y .

18(Original). A compound according to claim 17 wherein R_6 is C_{1-10} alkyl, $(\text{CH}_2)_n\text{C}_{6-10}$ aryl, $(\text{CH}_2)_n\text{C}_{5-10}$ heteroaryl, $(\text{CH}_2)_n\text{C}_{3-10}$ heterocyclyl, or $(\text{CH}_2)_n\text{C}_{3-8}$ cycloalkyl, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a , Y is $-\text{CO}(\text{CH}_2)_n$, Q is N, and R_2 and R_3 are independently selected from C_{1-10} alkyl, $(\text{CH}_2)_n\text{C}_{3-8}$ cycloalkyl, $-(\text{CH}_2)_n$ -5~10-membered heteroaryl, $-(\text{CH}_2)_n\text{C}_{6-10}$ aryl, $-(\text{CH}_2)_n$ -3~10-membered heterocyclyl, and C_{1-6} alkylOH said cycloalkyl, aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a .

19(Currently amended). A compound which is:
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(5-Methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
Methyl [2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetate,
Methyl [2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetate,
[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-bis(3-methylbutyl)acetamide,
~~1-(Diethoxymethyl)-6-methoxy-1*H*-benzimidazole,~~
~~1-(diethoxymethyl)-5-methoxy-1*H*-benzimidazole,~~
1-(6-Methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-diisobutylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-bis(3-methylbutyl)acetamide,
N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-diisobutylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
N-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(1-Benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-[1-(3,3-Dimethylbutyl)-5-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
1-[1-(3,3-Dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
N,N-Dibutyl-2-[2-(2,2-dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,
N,N-Dibutyl-2-[2-(2,2-dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
1-[2-(2,2-Dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[2-(2,2-Dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[5-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[6-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(5-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(6-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,

1-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dibutylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-butyl-*N*-ethylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(*tert*-butyl)-*N*-ethylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
[6-methoxy-1-(3-methylbutyl)-1*H*-benzimidazol-2-yl](phenyl)methanone,
[1-(2-ethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,
[1-(3,3-dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,
N-benzyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
N,N-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N,N-diisobutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,
N-(cyclopropylmethyl)-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,
N-butyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-cyclohexyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
1-(1-{2-[*trans*-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-{2-[*cis*-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-(2,2-dimethylpropyl)-*N*-ethylacetamide,
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,

2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-diisobutylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
2-{2-[(4-*trans*-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
N-(3,3-dimethylbutyl)-2-{2-[(4-*trans*-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[(4-*trans*-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
N,N-bis(3,3-dimethylbutyl)-2-{2-[(4-*trans*-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
2-{2-[(4-*cis*-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
N,N-diethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-diisobutylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,
~~1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2,2-dimethylpropan-1-one,~~
~~1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2-methylpropan-1-one,~~
1-(2-benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(5-methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-[5-methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

20(Original). A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of structural formula I of claim 16.

21(Original). A method for treating macular edema or macular degeneration, comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 16; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

22(Original). A composition comprising a compound of formula I of claim 16 and a pharmaceutically acceptable carrier.

23(Original). The composition according to Claim 22 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

24(Original). A composition according to claim 23 optionally containing one or more of a β -adrenergic blocking agent selected from the group consisting of timolol, betaxolol, levobetaxolol, carteolol, and levobunolol; a parasympathomimetic agent selected from the group consisting of pilocarpine; a sympathomimetic agent selected from the group consisting of epinephrine, brimonidine, iopidine, clonidine, and para-aminoclonidine, a carbonic anhydrase inhibitor selected from the group consisting of dorzolamide, acetazolamide, metazolamide and brinzolamide; a prostaglandin selected from the group consisting of latanoprost, travaprost, unoprostone, rescula, and S1033, a hypotensive lipid selected from the group consisting of lumigan, a neuroprotectant selected from the group consisting of eliprotil, R-eliprotil and memantine; and a 5-HT₂ receptor agonist selected from the group consisting of 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate and 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.